Robert W. Baird analyst Whit Mayo upgraded his AmSurg rating Friday to 'outperform' from 'neutral.' Mayo also boosted his price target for the company to $55 from $44.
Shares of the ambulatory surgery company (Ticker: AMSG ) were down nearly 10 percent last week, following news that the company is offering almost 10 million shares  to finance its acquisition of Sheridan Healthcare. Year to date, shares are down slightly. However, they're up 28 percent in the last 12 months.